LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy (LAPLACE)

November 10, 2022 updated by: Amgen

LAPLACE TIMI 57 - A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects

To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a statin in adults with hypercholesterolemia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

631

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
      • Quebec, Canada, G1V 4M6
        • Research Site
    • British Columbia
      • Burnaby, British Columbia, Canada, V5G 1T4
        • Research Site
      • Kelowna, British Columbia, Canada, V1Y 1V6
        • Research Site
      • Vancouver, British Columbia, Canada, V6Z 1Y6
        • Research Site
      • Victoria, British Columbia, Canada, V8T 5G1
        • Research Site
    • Ontario
      • Cambridge, Ontario, Canada, N1R 6V6
        • Research Site
      • Hamilton, Ontario, Canada, L8L 2X2
        • Research Site
      • London, Ontario, Canada, N5W 6A2
        • Research Site
      • London, Ontario, Canada, N6A 5K8
        • Research Site
      • Newmarket, Ontario, Canada, L3Y 5G8
        • Research Site
      • Oshawa, Ontario, Canada, L1J 2K1
        • Research Site
      • Oshawa, Ontario, Canada, L1J 2J9
        • Research Site
      • Sarnia, Ontario, Canada, N7T 4X3
        • Research Site
      • Scarborough, Ontario, Canada, M1P 2T7
        • Research Site
      • Sudbury, Ontario, Canada, P3C 5K7
        • Research Site
      • Toronto, Ontario, Canada, M9V 4B4
        • Research Site
      • Toronto, Ontario, Canada, M8V 3X8
        • Research Site
      • Woodstock, Ontario, Canada, N4S 5P5
        • Research Site
    • Quebec
      • Gatineau, Quebec, Canada, J8Y 6S9
        • Research Site
      • Lachine, Quebec, Canada, H8S 2E4
        • Research Site
      • Longueuil, Quebec, Canada, J4N 0C9
        • Research Site
      • Pointe-Claire, Quebec, Canada, H9R 3J1
        • Research Site
  • Czechia
      • Brno, Czechia, 625 00
        • Research Site
      • Brno, Czechia, 656 91
        • Research Site
      • Brno, Czechia, 603 00
        • Research Site
      • Olomouc, Czechia, 775 20
        • Research Site
      • Praha 2, Czechia, 120 00
        • Research Site
      • Praha 4, Czechia, 140 21
        • Research Site
      • Slany, Czechia, 274 01
        • Research Site
      • Svitavy, Czechia, 568 25
        • Research Site
      • Usti nad Orlici, Czechia, 562 18
        • Research Site
      • Znojmo, Czechia, 669 02
        • Research Site
  • Denmark
      • Aalborg, Denmark, 9000
        • Research Site
      • Ballerup, Denmark, 2750
        • Research Site
      • Vejle, Denmark, 7100
        • Research Site
  • Hungary
      • Budapest, Hungary, 1096
        • Research Site
      • Debrecen, Hungary, 4032
        • Research Site
      • Dunaujvaros, Hungary, 2400
        • Research Site
      • Eger, Hungary, 3300
        • Research Site
      • Gyula, Hungary, 5700
        • Research Site
      • Kecskemet, Hungary, 6000
        • Research Site
      • Komarom, Hungary, 2991
        • Research Site
      • Mosonmagyarovar, Hungary, 9200
        • Research Site
      • Szolnok, Hungary, 5004
        • Research Site
      • Zalaegerszeg, Hungary, 8900
        • Research Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Research Site
    • Arizona
      • Tucson, Arizona, United States, 85710
        • Research Site
    • Arkansas
      • Malvern, Arkansas, United States, 72104
        • Research Site
    • California
      • Anaheim, California, United States, 92801
        • Research Site
      • Carmichael, California, United States, 95608
        • Research Site
      • Newport Beach, California, United States, 92663
        • Research Site
      • Roseville, California, United States, 95747
        • Research Site
      • Westlake Village, California, United States, 91361
        • Research Site
    • Colorado
      • Colorado Springs, Colorado, United States, 80909
        • Research Site
      • Littleton, Colorado, United States, 80120
        • Research Site
    • Florida
      • Daytona Beach, Florida, United States, 32117
        • Research Site
      • Green Cove Springs, Florida, United States, 32043
        • Research Site
      • Melbourne, Florida, United States, 32901
        • Research Site
      • Miami, Florida, United States, 33173
        • Research Site
      • Miami, Florida, United States, 33143
        • Research Site
      • Port Charlotte, Florida, United States, 33952
        • Research Site
    • Illinois
      • Peoria, Illinois, United States, 61614
        • Research Site
    • Indiana
      • Hammond, Indiana, United States, 46320
        • Research Site
      • Indianapolis, Indiana, United States, 46237
        • Research Site
      • Valparaiso, Indiana, United States, 46383
        • Research Site
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • Research Site
    • Kentucky
      • Lexington, Kentucky, United States, 40536
        • Research Site
    • Maine
      • Auburn, Maine, United States, 04210
        • Research Site
      • Bangor, Maine, United States, 04401
        • Research Site
      • Portland, Maine, United States, 04101
        • Research Site
    • Michigan
      • Kalamazoo, Michigan, United States, 49048
        • Research Site
      • Marquette, Michigan, United States, 49855
        • Research Site
      • Ypsilanti, Michigan, United States, 48197
        • Research Site
    • Mississippi
      • Tupelo, Mississippi, United States, 38801
        • Research Site
    • Montana
      • Great Falls, Montana, United States, 59405
        • Research Site
    • New Jersey
      • Voorhees, New Jersey, United States, 08043
        • Research Site
    • New York
      • Cortlandt Manor, New York, United States, 10567
        • Research Site
      • Williamsville, New York, United States, 14221
        • Research Site
    • North Carolina
      • Smithfield, North Carolina, United States, 27577
        • Research Site
      • Winston-Salem, North Carolina, United States, 27103
        • Research Site
    • Ohio
      • Canton, Ohio, United States, 44708
        • Research Site
      • Cincinnati, Ohio, United States, 45219
        • Research Site
      • Cincinnati, Ohio, United States, 45212
        • Research Site
      • Dayton, Ohio, United States, 45414
        • Research Site
      • Mansfield, Ohio, United States, 44906
        • Research Site
      • Marion, Ohio, United States, 43302
        • Research Site
      • Sandusky, Ohio, United States, 44870
        • Research Site
    • Pennsylvania
      • Camp Hill, Pennsylvania, United States, 17011
        • Research Site
      • Philadelphia, Pennsylvania, United States, 19104
        • Research Site
      • Pittsburgh, Pennsylvania, United States, 15216
        • Research Site
      • York, Pennsylvania, United States, 17405
        • Research Site
    • South Carolina
      • Florence, South Carolina, United States, 29501
        • Research Site
      • Spartanburg, South Carolina, United States, 29302
        • Research Site
    • South Dakota
      • Rapid City, South Dakota, United States, 57701
        • Research Site
    • Tennessee
      • Jackson, Tennessee, United States, 38305
        • Research Site
      • Jackson, Tennessee, United States, 38301
        • Research Site
    • Texas
      • Houston, Texas, United States, 77074
        • Research Site
      • Houston, Texas, United States, 77002
        • Research Site
    • Washington
      • Tacoma, Washington, United States, 98405
        • Research Site
    • Wisconsin
      • Madison, Wisconsin, United States, 53713
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female ≥ 18 to ≤ 80 years of age
  • On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks
  • Fasting LDL-C ≥ 85 mg/dL
  • Fasting triglycerides ≤ 400 mg/dL

Exclusion Criteria:

  • Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization
  • Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (Glycosyated Hemoglobin (HbA1c) > 8.5%)
  • Uncontrolled hypertension
  • New York Heart Association (NYHA) III or IV heart failure, or known left ventricular ejection fraction < 30%
  • Uncontrolled cardiac arrhythmia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Placebo Q2W
Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
Other: Placebo to Evolocumab
Administered by subcutaneous injection
PLACEBO_COMPARATOR: Placebo Q4W
Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
Other: Placebo to Evolocumab
Administered by subcutaneous injection
EXPERIMENTAL: Evolocumab 70 mg Q2W
Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Other Names:
  • Repatha
  • AMG 145
EXPERIMENTAL: Evolocumab 105 mg Q2W
Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Other Names:
  • Repatha
  • AMG 145
EXPERIMENTAL: Evolocumab 140 mg Q2W
Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Other Names:
  • Repatha
  • AMG 145
EXPERIMENTAL: Evolocumab 280 mg Q4W
Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Other Names:
  • Repatha
  • AMG 145
EXPERIMENTAL: Evolocumab 350 mg Q4W
Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Other Names:
  • Repatha
  • AMG 145
EXPERIMENTAL: Evolocumab 420 mg Q4W
Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Other Names:
  • Repatha
  • AMG 145

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Time Frame: Baseline and Week 12
LDL-C was measured using ultracentrifugation.
Baseline and Week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent Change From Baseline in Apolipoprotein B at Week 12
Time Frame: Baseline and Week 12
Baseline and Week 12
Change From Baseline in LDL-C at Week 12
Time Frame: Baseline and Week 12
LDL-C was measured using ultracentrifugation.
Baseline and Week 12
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Time Frame: Baseline and Week 12
Baseline and Week 12
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
Time Frame: Baseline and Week 12
Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
Time Frame: Baseline and Week 12
Baseline and Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Amgen

Collaborators

TIMI Study Group

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 1, 2011

Primary Completion (ACTUAL)

April 5, 2012

Study Completion (ACTUAL)

April 5, 2012

Study Registration Dates

First Submitted

June 23, 2011

First Submitted That Met QC Criteria

June 23, 2011

First Posted (ESTIMATE)

June 27, 2011

Study Record Updates

Last Update Posted (ACTUAL)

November 15, 2022

Last Update Submitted That Met QC Criteria

November 10, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20101155

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperlipidemia

Clinical Trials on Evolocumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe